Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Avadel Pharmaceuticals PLC

AVDL
Current price
8.61 USD -0.38 USD (-4.23%)
Last closed 8.33 USD
ISIN US05337M1045
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Exchange NASDAQ
Capitalization 1 266 844 672 USD
Yield for 12 month -36.55 %
1Y
3Y
5Y
10Y
15Y
AVDL
21.11.2021 - 28.11.2021

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Address: 10 Earlsfort Terrace, Dublin, Ireland, 2

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

24.70 USD

P/E ratio

Dividend Yield

Current Year

+27 963 000 USD

Last Year

+1 496 000 USD

Current Quarter

+50 025 000 USD

Last Quarter

+41 504 000 USD

Current Year

+27 117 000 USD

Last Year

-1 493 000 USD

Current Quarter

+43 870 000 USD

Last Quarter

+38 716 000 USD

Key Figures AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -97 231 000 USD
Operating Margin TTM -30.70 %
PE Ratio
Return On Assets TTM -34.45 %
PEG Ratio 0.070
Return On Equity TTM -99.52 %
Wall Street Target Price 24.70 USD
Revenue TTM 95 149 000 USD
Book Value 0.98 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 2 674.30 %
Dividend Yield
Gross Profit TTM 16 592 000 USD
Earnings per share -1.09 USD
Diluted Eps TTM -1.09 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin -111.64 %

Dividend Analytics AVDL

Max Ratio

>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Dividend History AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date
Consecutive Years
Consistent Years
Continuous Dividends

Stock Valuation AVDL

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE 16.31
Enterprise Value Revenue 7.16
Price Sales TTM 7.62
Enterprise Value EBITDA -6.43
Price Book MRQ 14.11

Financials AVDL

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators AVDL

For 52 weeks

9.41 USD 19.09 USD
50 Day MA 13.67 USD
Shares Short Prior Month 8 814 536
200 Day MA 15.28 USD
Short Ratio 12.45
Shares Short 9 786 822
Short Percent 12.10 %